INNATE PHARMA SA

Innate Pharma shares dip 0.15% to €1.30, near 200‑day SMA €1.49, as the company announces upcoming Stifel & Jefferies conferences and key antibody‑drug partnerships.

Innate Pharma spikes 6.6% ahead of Q3 update, driven by Nectin‑4 ADC progress and big-name partnerships with AstraZeneca and Sobi.